Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
33.49
-0.95 (-2.76%)
May 7, 2026, 2:20 PM EDT - Market open
Qiagen Employees
Qiagen had 5,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$368,222
Profits / Employee
$70,555
Market Cap
6.93B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,700 | 0 | - |
| Dec 31, 2024 | 5,700 | -267 | -4.47% |
| Dec 31, 2023 | 5,967 | -211 | -3.42% |
| Dec 31, 2022 | 6,178 | 150 | 2.49% |
| Dec 31, 2021 | 6,028 | 418 | 7.45% |
| Dec 31, 2020 | 5,610 | 514 | 10.09% |
| Dec 31, 2019 | 5,096 | 144 | 2.91% |
| Dec 31, 2018 | 4,952 | 264 | 5.63% |
| Dec 31, 2017 | 4,688 | 4 | 0.09% |
| Dec 31, 2016 | 4,684 | 125 | 2.74% |
| Dec 31, 2015 | 4,559 | 220 | 5.07% |
| Dec 31, 2014 | 4,339 | 324 | 8.07% |
| Dec 31, 2013 | 4,015 | 16 | 0.40% |
| Dec 31, 2012 | 3,999 | 61 | 1.55% |
| Dec 31, 2011 | 3,938 | 351 | 9.79% |
| Dec 31, 2010 | 3,587 | 92 | 2.63% |
| Dec 31, 2009 | 3,495 | 454 | 14.93% |
| Dec 31, 2008 | 3,041 | 379 | 14.24% |
| Dec 31, 2007 | 2,662 | 708 | 36.23% |
| Dec 31, 2006 | 1,954 | 365 | 22.97% |
| Dec 31, 2005 | 1,589 | 267 | 20.20% |
| Dec 31, 2004 | 1,322 | -231 | -14.87% |
| Dec 31, 2003 | 1,553 | -98 | -5.94% |
| Dec 31, 2002 | 1,651 | 94 | 6.04% |
| Dec 31, 2001 | 1,557 | 242 | 18.40% |
| Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| ICON Public Limited Company | 41,900 |
| Charles River Laboratories International | 19,700 |
| Revvity | 11,000 |
| RadNet | 9,276 |
| Medpace Holdings | 6,200 |
| Sotera Health Company | 3,000 |
| Guardant Health | 2,506 |
| Twist Bioscience | 979 |
QGEN News
- 4 hours ago - Qiagen Transcript: Status update - Transcripts
- 8 hours ago - QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing - Business Wire
- 17 hours ago - Qiagen reports Q1 EPS 54c, consensus 54c - TheFly
- 19 hours ago - QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 22 hours ago - QIAGEN Reports Full Results for Q1 2026 - Business Wire
- 7 days ago - Qiagen price target lowered to $43 from $54 at Deutsche Bank - TheFly
- 8 days ago - Qiagen price target lowered to EUR 34 from EUR 44 at Morgan Stanley - TheFly
- 8 days ago - Qiagen price target lowered to $45 from $60 at JPMorgan - TheFly